Market Overview

Why The Biotech Boom Is Still In The 1st Inning

Share:
Why The Biotech Boom Is Still In The 1st Inning
Related GILD
Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock
Jim Cramer Advises His Viewers On Seagate, Centurylink And Gilead
Founders Capital Management, Llc Buys Baker Hughes Inc, UnitedHealth Group Inc, Sells Gilead ... (GuruFocus)
Related BDSI
22 Stocks Moving In Wednesday's Pre-Market Session
Mid-Afternoon Market Update: Crude Oil Down 3%; La-Z-Boy Shares Gain On Earnings Beat

For This Week on Estimize, CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights.

Joe explains why he believes the biotech boom still has plenty of legs, and Leigh and Joe discuss how to value pharmaceutical stocks.

The discussion covers specific names including Gilead Sciences, Inc. (NASDAQ: GILD), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Retrophin Inc (NASDAQ: RTRX) and Auspex Pharmaceuticals Inc (NASDAQ: ASPX).

Image credit: Jeffrey Beall, Wikimedia

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Biotech BoomLong Ideas Trading Ideas Best of Benzinga

 

Related Articles (BDSI + ASPX)

View Comments and Join the Discussion!